Cargando…
Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
INTRODUCTION: Glucagon-like peptide-1 (GLP-1) is an endogenous peptide that stimulates insulin secretion and decreases glucagon secretion. The use of GLP-1 receptor agonists (GLP-1RA) showed efficacy reducing the weight and glucose levels in patients with and without type 2 diabetes. This effect was...
Autores principales: | Delgado, A., Velosa, J., Avelar, R., Franco, J., Heitor, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479982/ http://dx.doi.org/10.1192/j.eurpsy.2021.2050 |
Ejemplares similares
-
PM426. Effect of a glucagon-like peptide 1 (GLP-1) receptor agonist, liraglutide, on cognition and body weight during antipsychotic treatment
por: Babic, I, et al.
Publicado: (2016) -
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
por: Baggio, Laurie L., et al.
Publicado: (2020) -
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017) -
Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016) -
How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)